Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Dahut Website

William L. Dahut, M.D.

Selected Publications

1)  Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD.
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
J Clin Oncol. 22: 2532-9, 2004.
[Journal]
2)  Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clin. Cancer Res. 11: 3353-62, 2005.
[Journal]
3)  Sharifi N, Gulley JL, Dahut WL.
Androgen deprivation therapy for prostate cancer.
JAMA. 294: 238-44, 2005.
[Journal]
4)  Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W.
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Clin. Cancer Res. 12: 1260-9, 2006.
[Journal]
5)  Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 2070-6, 2010.
[Journal]
6)  Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Cancer Immunol. Immunother. 63: 407-18, 2014.
[Journal]
7)  Adesunloye BA, Karzai FH, Dahut WL.
Angiogenesis inhibitors in the treatment of prostate cancer.
Chem Immunol Allergy. 99: 197-215, 2014.
[Journal]
8)  Madan RA, Shah AA, Dahut WL.
Is it time to reevaluate definitive therapy in prostate cancer?.
J. Natl. Cancer Inst. 105: 683-5, 2013.
[Journal]
9)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 62: 1521-31, 2013.
[Journal]
10)  Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD.
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
BJU Int. 111: 1269-80, 2013.
[Journal]
11)  Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.
Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity.
Clin Genitourin Cancer. 11: 229-37, 2013.
[Journal]
12)  Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, Compton K, Dahut WL, Figg WD, Citrin D, Camphausen KA.
Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.
Biomark Med. 7: 831-41, 2013.
[Journal]
13)  Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 13: 501-8, 2012.
[Journal]
14)  Kamrava M, Kesarwala AH, Madan RA, Lita E, Kaushal A, Tsang K, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL.
Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.
Prostate Cancer Prostatic Dis. 15: 289-95, 2012.
[Journal]
15)  Gulley JL, Leitman SF, Dahut W, Schlom J.
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
J. Natl. Cancer Inst. 104: 1106; author reply 1109-12, 2012.
[Journal]
16)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012.
[Journal]
17)  Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, Madan RA, Landgren O, Choyke PL.
The Kinetics and Reproducibility of 18F-Sodium Fluoride for Oncology Using Current PET Camera Technology.
J. Nucl. Med. 53: 1175-84, 2012.
[Journal]
18)  Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Clin. Cancer Res. 17: 7164-73, 2011.
[Journal]
19)  Bilusic M, Dahut WL.
Cabazitaxel: a new drug for metastatic prostate cancer.
Asian J. Androl. 13: 185-6, 2011.
[Journal]
20)  Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL.
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.
Expert Rev Vaccines. 10: 743-53, 2011.
[Journal]
21)  Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL, Miller JL.
Hepcidin, anaemia, and prostate cancer.
BJU Int. 107: 678-9, 2011.
[Journal]
22)  Madan RA, Pal SK, Sartor O, Dahut WL.
Overcoming chemotherapy resistance in prostate cancer.
Clin. Cancer Res. 17: 3892-902, 2011.
[Journal]
23)  Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD.
Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors.
Br J Clin Pharmacol. 72: 294-305, 2011.
[Journal]
24)  Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T.
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
Clin. Cancer Res. 17: 907-17, 2011.
[Journal]
25)  Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD.
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Pharmacogenomics J. 10: 191-9, 2010.
[Journal]
26)  Figg WD, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL.
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
J. Urol. 183: 2219-26, 2010.
[Journal]
27)  English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD.
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.
Ther Clin Risk Manag. 6: 579-83, 2010.
[Journal]
28)  Aragon-Ching JB, Dahut WL.
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?.
Ann. Oncol. 21: 183-4, 2010.
[Journal]
29)  Sharifi N, Gulley JL, Dahut WL.
An update on androgen deprivation therapy for prostate cancer.
Endocr. Relat. Cancer. 17: R305-15, 2010.
[Journal]
30)  Aragon-Ching JB, Madan RA, Dahut WL.
Angiogenesis inhibition in prostate cancer: current uses and future promises.
J Oncol. 2010: 361836, 2010.
[Journal]
31)  Kluetz PG, Figg WD, Dahut WL.
Angiogenesis inhibitors in the treatment of prostate cancer.
Expert Opin Pharmacother. 11: 233-47, 2010.
[Journal]
32)  Gao R, Price DK, Dahut WL, Steinberg SM, Reed E, Figg WD.
Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.
Cancer Biol Ther. 10: 13-8, 2010.
[Journal]
33)  Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
J. Exp. Clin. Cancer Res. 29: 95, 2010.
[Journal]
34)  Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol. Immunother. 59: 663-74, 2010.
[Journal]
35)  Aragon-Ching JB, Dahut WL.
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.
Drug Discov Today Ther Strateg. 7: 31-35, 2010.
[Journal]
36)  Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 1099-105, 2010.
[Journal]
37)  Dahut WL, Madan RA.
Revisiting the ultimate target of treatment for prostate cancer.
Lancet. 375: 1409-10, 2010.
[Journal]
38)  Madan RA, Gulley JL, Fojo T, Dahut WL.
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.
Oncologist. 15: 969-75, 2010.
[Journal]
39)  Zhu W, Dahut WL.
Tumor angiogenesis as an early marker of long-term prostate cancer mortality.
Future Oncol. 6: 341-5, 2010.
[Journal]
40)  Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL.
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
J. Urol. 181: 1104-13; discussion 1113, 2009.
[Journal]
41)  Madan RA, Dahut WL.
Angiogenesis inhibition in the treatment of prostate cancer.
Anticancer Agents Med Chem. 9: 1070-8, 2009.
[Journal]
42)  Aragon-Ching JB, Dahut WL.
Anti-angiogenesis approach to genitourinary cancer treatment.
Update Cancer Ther. 3: 182-188, 2009.
[Journal]
43)  Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL.
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
BJU Int. 103: 1636-40, 2009.
[Journal]
44)  Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH.
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Clin. Cancer Res. 15: 1411-6, 2009.
[Journal]
45)  Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL.
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer Invest. 27: 221-6, 2009.
[Journal]
46)  Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD.
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
J Clin Pharmacol. 49: 650-60, 2009.
[Journal]
47)  Ning Y, Figg WD, Dahut WL.
Reversal of Docetaxel Resistance With Bevacizumab and Thalidomide.
Clin Genitourin Cancer. 7: E37-E38, 2009.
[Journal]
48)  Zhu W, Zhu DS, Madan RA, Gulley JL, Figg WD, Dahut WL.
Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.
Am J Ther. 17: 176-81, 2009.
[Journal]
49)  Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K.
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
Clin. Cancer Res. 15: 4292-8, 2009.
[Journal]
50)  Aragon-Ching JB, Dahut WL.
VEGF Inhibitors and Prostate Cancer Therapy.
Curr Mol Pharmacol. 2: 161-168, 2009.
[Journal]
51)  Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD.
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Clin. Cancer Res. 14: 209-14, 2008.
[Journal]
52)  Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD.
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
BJU Int. 102: 617-21, 2008.
[Journal]
53)  Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD.
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Clin. Cancer Res. 14: 4543-9, 2008.
[Journal]
54)  Aragon-Ching JB, Ning Y, Dahut WL.
Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab.
Acta Oncol. 1-3, 2008.
[Journal]
55)  Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM.
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Clin. Cancer Res. 14: 4526-31, 2008.
[Journal]
56)  Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, Dahut WL, Figg WD.
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
BJU Int. 102: 1694-9, 2008.
[Journal]
57)  Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A.
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Mol. Cancer Ther. 7: 19-26, 2008.
[Journal]
58)  Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, Marshall FF, Chung LW.
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.
Cancer Res. 68: 9996-10003, 2008.
[Journal]
59)  Jain L, Gardner ER, Venitz J, Dahut W, Figg WD.
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
Journal of pharmaceutical and biomedical analysis. 46: 362-7, 2008.
[Journal]
60)  Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD.
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clin. Cancer Res. 14: 3312-8, 2008.
[Journal]
61)  Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL.
Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer.
J. Urol. 2008.
[Journal]
62)  Aragon-Ching JB, Dahut WL.
Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association?.
Oncologist. 13: 1314; author reply 1315, 2008.
[Journal]
63)  Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J.
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Clin. Cancer Res. 14: 3060-9, 2008.
[Journal]
64)  Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O.
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
J. Urol. 179: 2181-5; discussion 2185-6, 2008.
[Journal]
65)  Gardner ER, Dahut W, Figg WD.
Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 862: 213-8, 2008.
[Journal]
66)  Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD.
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Clin. Cancer Res. 14: 4200-5, 2008.
[Journal]
67)  Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL.
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Clin. Cancer Res. 14: 5284-91, 2008.
[Journal]
68)  Sharifi N, Dahut WL, Figg WD.
Secondary hormonal therapy for prostate cancer: what lies on the horizon?.
BJU Int. 101: 271-4, 2008.
[Journal]
69)  Sharifi N, Dahut WL, Figg WD.
The genetics of castration-resistant prostate cancer: what can the germline tell us?.
Clin. Cancer Res. 14: 4691-3, 2008.
[Journal]
70)  Aragon-Ching JB, Dahut WL.
The role of angiogenesis inhibitors in prostate cancer.
Cancer J. 14: 20-5, 2008.
[Journal]
71)  Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T.
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.
Oncologist. 13: 1046-54, 2008.
[Journal]
72)  Srinivasan R, Armstrong AJ, Dahut W, George DJ.
Anti-angiogenic therapy in renal cell cancer.
BJU Int. 99: 1296-300, 2007.
[Journal]
73)  Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, Figg WD.
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Urology. 70: 217-20, 2007.
[Journal]
74)  Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL, Figg WD.
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.
J Pharm Sci. 96: 1821-31, 2007.
[Journal]
75)  Aragon-Ching JB, Dahut WL.
Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?.
Cancer Ther. 5A: 151-160, 2007.
[Journal]
76)  Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL.
Clinical safety of a viral vector based prostate cancer vaccine strategy.
J Urol. 178: 1515-20, 2007.
[Journal]
77)  Gulley JL, Dahut WL.
Future directions in tumor immunotherapy: CTLA4 blockade.
Nat Clin Pract Oncol. 4: 136-7, 2007.
[Journal]
78)  Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML.
Keratoacanthomas associated with sorafenib therapy.
J. Am. Acad. Dermatol. 56: 171-2, 2007.
[Journal]
79)  Aragon-Ching JB, Gillespie J, Price DK, Chuaqui R, Rodriguez-Canales J, Steinberg SM, Dahut WL, Figg WD.
Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer.
BJU Int. 100: 1245-8, 2007.
[Journal]
80)  Gulley JL, Wu S, Arlen PM, Dahut WL.
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Clin Genitourin Cancer. 5: 403-5, 2007.
[Journal]
81)  Theoret MR, Arlen PM, Pazdur M, Dahut WL, Schlom J, Gulley JL.
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
Clin Genitourin Cancer. 5: 347-50, 2007.
[Journal]
82)  Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W.
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
BJU Int. 99: 1047-55, 2007.
[Journal]
83)  Zhu X, Wu S, Dahut WL, Parikh CR.
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
Am. J. Kidney Dis. 49: 186-93, 2007.
[Journal]
84)  Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, Figg WD, Dahut WL.
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
BJU Int. 99: 525-8, 2007.
[Journal]
85)  Madan RA, Lieberman R, Gulley JL, Dahut W, Arlen PM.
Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature.
Am J Ther. 14: 310-3, 2007.
[Journal]
86)  Wu S, Dahut WL, Gulley JL.
The use of bisphosphonates in cancer patients.
Acta Oncol. 46: 581-91, 2007.
[Journal]
87)  Gulley JL, Parnes HL, Wright J, Dahut WL.
Early treatment gets the benefit.
J. Clin. Oncol. 24: 5172-3; author reply 5173, 2006.
[Journal]
88)  Arlen PM, Dahut WL, Gulley JL.
Immunotherapy for prostate cancer: what's the future?.
Hematol. Oncol. Clin. North Am. 20: 965-83, xi, 2006.
[Journal]
89)  Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD.
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer Biol. Ther. 5: 22-7, 2006.
[Journal]
90)  Lakhani N, Sparreboom A, Venitz J, Dahut WL, Figg WD.
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
Anticancer Drugs. 17: 977-83, 2006.
[Journal]
91)  Rozhansky F, Chen MH, Cox MC, Dahut W, Figg WD, D'Amico AV.
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
Cancer. 106: 63-7, 2006.
[Journal]
92)  Cox MC, Dahut WL, Figg WD.
The use of thalidomide in androgen-independent prostate cancer.
Urol. Oncol. 24: 246-9, 2006.
[Journal]
93)  Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL.
A phase II study of perifosine in androgen independent prostate cancer.
Cancer Biol. Ther. 4: 1133-7, 2005.
[Journal]
94)  Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL.
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
J. Urol. 173: 1567-71, 2005.
[Journal]
95)  Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Cox MC, Zhai S, Cremers S, Parr A, Yang X, Chen CC, Jones E, Dahut WL.
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
J. Urol. 173: 790-6, 2005.
[Journal]
96)  Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, Gulley JL.
A retrospective study of the time to clinical endpoints for advanced prostate cancer.
BJU international. 96: 985-9, 2005.
[Journal]
97)  Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW, Schlom J, Dahut W.
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
J. Urol. 174: 539-46, 2005.
[Journal]
98)  Gulley J, Dahut WL.
Clodronate in the prevention and treatment of skeletal metastasis.
Expert Rev Anticancer Ther. 5: 221-30, 2005.
[Journal]
99)  Lakhani NJ, Lepper ER, Sparreboom A, Dahut WL, Venitz J, Figg WD.
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.
Rapid Commun. Mass Spectrom. 19: 1176-82, 2005.
[Journal]
100)  Boyiadzis M, Nam M, Dahut W.
Fulminant hepatic failure secondary to metastatic prostate cancer.
Urol Int. 74: 185-7, 2005.
[Journal]
101)  Ghosh L, Dahut W, Kakar S, Posadas EM, Torres CG, Cancel-Santiago R, Ghosh BC.
Management of patients with metastatic cancer of unknown primary.
Curr Probl Surg. 42: 12-66, 2005.
[Journal]
102)  Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD.
Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.
Cancer Biol. Ther. 4: 1222-5, 2005.
[Journal]
103)  Todd NF, Lieberman R, Gulley JL, Dahut W, Arlen PM.
Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy.
Am J Ther. 12: 172-4, 2005.
[Journal]
104)  D'Amico AV, Chen MH, Cox MC, Dahut W, Figg WD.
Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
Urology. 66: 571-6, 2005.
[Journal]
105)  Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, Figg WD.
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Clin Prostate Cancer. 2: 241-3, 2004.
[Journal]
106)  Gulley J, Dahut WL.
Chemotherapy for prostate cancer: finally an advance!.
Am J Ther. 11: 288-94, 2004.
[Journal]
107)  Tohnya TM, Hwang K, Lepper ER, Fine HA, Dahut WL, Venitz J, Sparreboom A, Figg WD.
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 811: 135-41, 2004.
[Journal]
108)  Lakhani NJ, Sparreboom A, Dahut WL, Venitz J, Figg WD.
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection.
J Chromatogr B Analyt Technol Biomed Life Sci. 806: 289-93, 2004.
[Journal]
109)  Macpherson GR, Singh AS, Bennett CL, Venzon DJ, Liewehr DJ, Franks ME, Dahut WL, Kantoff PW, Price DK, Figg WD.
Genotyping and functional analysis of the D104N variant of human endostatin.
Cancer Biol. Ther. 3: 1298-303, 2004.
[Journal]
110)  Retter AS, Gulley JL, Dahut WL.
Novel therapeutic strategies in prostate cancer.
Cancer Biol Ther. 3: 371-6, 2004.
[Journal]
111)  Posadas EM, Dahut WL, Gulley J.
The emerging role of bisphosphonates in prostate cancer.
Am J Ther. 11: 60-73, 2004.
[Journal]
112)  Arlen PM, Gulley JL, Dahut W.
Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans.
Am J Ther. 11: 238-41, 2004.
[Journal]
113)  Leguizamo J, Quinn M, Takimoto CH, Liang MD, Ismail AS, Pang J, Dahut W, Grem JL.
A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
Cancer Chemother Pharmacol. 2003.
[Journal]
114)  Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D, Duray P, Liewehr DJ, Lakhani N, Steinberg SM, Figg WD, Reed E.
A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer.
Acta Oncol. 42: 195-201, 2003.
[Journal]
115)  Leonard GD, Dahut WL, Gulley JL, Arlen PM, Figg WD.
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer.
Reviews in urology. 5 Suppl 3: S65-70, 2003.
[Journal]
116)  Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL.
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
J. Clin. Oncol. 21: 2664-72, 2003.
[Journal]
117)  Horne MK, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL.
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Pharmacotherapy. 23: 315-8, 2003.
[Journal]
118)  Gulley J, Dahut WL.
Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.
Urology. 62 Suppl 1: 147-54, 2003.
[Journal]
119)  Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD.
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.
Cancer Biol Ther. 1: 669-73, 2003.
[Journal]
120)  Leonard GD, Zhuang SH, Dahut W.
Prostate cancer metastatic to skin.
Urology. 61: 456-7, 2003.
[Journal]
121)  Behrens RJ, Gulley JL, Dahut WL.
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.
Am J Ther. 10: 228-32, 2003.
[Journal]
122)  Retter AS, Figg WD, Dahut WL.
The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer.
Clin Prostate Cancer. 2: 153-9, 2003.
[Journal]
123)  Gulley J, Figg WD, Dahut WL.
Treatment options for androgen-independent prostate cancer.
Clin Adv Hematol Oncol. 1: 49-57, 2003.
[Journal]
124)  Kurdziel KA, Figg WD, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, Libutti SK, Pluda JM, Dahut W, Reed E, Bacharach SL.
Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.
Mol Imaging Biol. 5: 86-93, 2003.
[Journal]
125)  Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ.
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.
J Exp Ther Oncol. 2: 325-32, 2002.
[Journal]
126)  Posadas EM, Dahut WL.
Approaches to inhibit invasiveness and metastasis in prostate cancer.
Clin prostate cancer. 1: 125, 2002.
[Journal]
127)  Figg WD, Kruger EA, Price DK, Kim S, Dahut WD.
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.
Invest New Drugs. 20: 183-94, 2002.
[Journal]
128)  Neelapu S, Figg WD, Dahut W, Reed E.
Leptomeningeal carcinomatosis in metastatic prostate cancer.
South Med J. 95: 107-8, 2002.
[Journal]
129)  Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W.
National Cancer Institute intramural approach to advanced prostate cancer.
Clin prostate cancer. 1: 153-62, 2002.
[Journal]
130)  Gulley J, Dahut W.
Novel clinical trials in androgen-independent prostate cancer.
Clin prostate cancer. 1: 51-7, 2002.
[Journal]
131)  Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J.
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Prostate. 53: 109-17, 2002.
[Journal]
132)  Kaur M, Reed E, Sartor O, Dahut W, Figg WD.
Suramin's development: what did we learn.
Invest New Drugs. 20: 209-19, 2002.
[Journal]
133)  Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ.
A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
Clin Cancer Res. 7: 3912-9, 2001.
[Journal]
134)  Thomas RR, Dahut W, Harold N, Grem JL, Monahan BP, Liang M, Band RA, Cottrell J, Llorens V, Smith JA, Corse W, Arbuck SG, Wright J, Chen AP, Shapiro JD, Hamilton JM, Allegra CJ, Takimoto CH.
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.
Cancer Chemother Pharmacol. 48: 215-22, 2001.
[Journal]
135)  Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL.
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Semin Oncol. 28: 62-6, 2001.
[Journal]
136)  Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Krüger EA, Gubish E, Pluda JM, Reed E.
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Clin Cancer Res. 7: 1888-93, 2001.
[Journal]
137)  Carrasquillo JA, Whatley M, Dyer V, Figg WD, Dahut W.
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.
J Nucl Med. 42: 1359-63, 2001.
[Journal]
138)  Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E.
Drug-induced lupus associated with COL-3: report of 3 cases.
Arch Dermatol. 137: 471-4, 2001.
[Journal]
139)  Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, Hanfelt J, Gehan E, Figuera M, Hawkins MJ, Rizvi NA.
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Cancer Chemother Pharmacol. 48: 95-103, 2001.
[Journal]
140)  Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E.
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
J Clin Oncol. 19: 584-92, 2001.
[Journal]
141)  Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E.
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.
Am J Hematol. 67: 51-3, 2001.
[Journal]
142)  Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD.
Thalidomide neuropathy in patients treated for metastatic prostate cancer.
Muscle Nerve. 24: 1050-7, 2001.
[Journal]
143)  Kurdziel K, Bacharach S, Carrasquillo J, Huebsch S, Whatley M, Sellers D, Steinberg S, Libutti S, Pluda J, Reed E, Dahut W, Figg W.
8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide.
Clin Positron Imaging. 3: 144, 2000.
[Journal]
144)  Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, Hawkins MJ.
A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
Clin Cancer Res. 6: 1259-66, 2000.
[Journal]
145)  Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ.
A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
Clin Cancer Res. 5: 1989-95, 1999.
[Journal]
146)  Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, Hawkins MJ.
A Phase I study of LGD1069 in adults with advanced cancer.
Clin Cancer Res. 5: 1658-64, 1999.
[Journal]
147)  Rizvi NA, Spiridonidis CH, Davis TH, Bhargava P, Marshall JL, Dahut W, Figuera M, Hawkins MJ.
Docetaxel and gemcitabine combinations in non-small cell lung cancer.
Semin Oncol. 26: 27-31; discussion 41-2, 1999.
[Journal]
148)  Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G.
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
J Clin Oncol. 17: 3461-7, 1999.
[Journal]
149)  Saif MW, Figg WD, Hewitt S, Brosky K, Reed E, Dahut W.
Malignant ascites as only manifestation of metastatic prostate cancer.
Prostate Cancer Prostatic Dis. 2: 290-293, 1999.
[Journal]
150)  Ornstein DK, Dahut WL, Liotta LA, Emmert-Buck MR.
Review of AACR meeting: new research approaches in the prevention and cure of prostate cancer, 2-6 December 1998, Indian Wells, CA.
Biochim Biophys Acta. 1424: R11-9, 1999.
[Journal]
151)  Kang MH, Figg WD, Dahut W.
Taxanes in hormone-refractory prostate cancer.
Cancer Pract. 7: 270-2, 1999.
[Journal]
152)  Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, Lieberman R, Arbuck SG, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL.
Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.
J Clin Oncol. 15: 1492-501, 1997.
[Journal]
153)  Mordkin RM, Dahut WL, Lynch JH.
Renal angiosarcoma: a rare primary genitourinary malignancy.
South Med J. 90: 1159-60, 1997.
[Journal]
154)  Monahan BP, Rector JT, Liu PP, Cotelingam JD, Dahut W.
Clinical aspects of expression of inversion 16 chromosomal fusion transcript CBFB/MYH11 in acute myelogenous leukemia subtype M1 with abnormal bone marrow eosinophilia.
Leukemia. 10: 1653-4, 1996.
[Journal]
155)  Takimoto CH, Dahut W, Harold N, Nakashima H, Lieberman R, Liang MD, Arbuck SG, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL.
Clinical pharmacology of 9-aminocamptothecin.
Ann N Y Acad Sci. 803: 324-6, 1996.
[Journal]
156)  Grem JL, Politi PM, Berg SL, Benchekroun NM, Patel M, Balis FM, Sinha BK, Dahut W, Allegra CJ.
Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells.
Biochem Pharmacol. 51: 1649-59, 1996.
[Journal]
157)  Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J.
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
J Clin Oncol. 14: 1236-44, 1996.
[Journal]
158)  Copur S, Dahut W, Chu E, Allegra CJ.
Bone marrow aplasia and severe skin rash after a single low dose of methotrexate.
Anticancer Drugs. 6: 154-7, 1995.
[Journal]
159)  Geoffroy F, Dahut W, Takimoto CH, Grem JL.
Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples.
Clin Cancer Res. 1: 1345-51, 1995.
[Journal]
160)  Politi PM, Xie F, Dahut W, Ford H, Kelley JA, Bastian A, Setser A, Allegra CJ, Chen AP, Hamilton JM.
Phase I clinical trial of continuous infusion cyclopentenyl cytosine.
Cancer Chemother Pharmacol. 36: 513-23, 1995.
[Journal]
161)  Dahut W, Georgiadis M.
Pneumococcal arthritis and functional asplenia after allogeneic bone marrow transplantation.
Bone Marrow Transplant. 15: 161, 1995.
[Journal]
162)  Takimoto CH, Klecker RW, Dahut WL, Yee LK, Strong JM, Allegra CJ, Grem JL.
Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography.
J Chromatogr B Biomed Appl. 655: 97-104, 1994.
[Journal]
163)  Riseberg DA, Mulvey KP, Dahut WL, Frame JN, Phares JC.
Late extramedullary relapse following bone marrow transplant for AML presenting as acute renal failure and leukemic ascites.
Bone Marrow Transplant. 14: 1009-10, 1994.
[Journal]
164)  Frame JN, Dahut WL, Crowley S.
Fludarabine and acute tumor lysis in chronic lymphocytic leukemia.
N Engl J Med. 327: 1396-7, 1992.
[Journal]
165)  Hyams KC, Cross ER, Bianco MA, Soyk-Sarty DR, Roper CM, Dahut WL, Holmberg JA.
Geographic risk factors for viral hepatitis and cytomegalovirus infection among United States Armed Forces blood donors.
Transfusion. 32: 644-7, 1992.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/18/2014.